lifestyle.celebhomes.net
Home
Sample Page
Author:
Zhongshan Kangfang Biological Medicine Co., LTD
Head-to-Head Real-World Data: Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer
January 14, 2026
Ivonescimab’s Updated Label Shows Positive Dual Results in PFS and OS from HARMONi-A Study
January 7, 2026
Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab
December 13, 2025
Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented at ESMO IO 2025
December 11, 2025
Phase II Data of Cadonilimab Regimen as Neoadjuvant Therapy for Resectable Gastric Cancer Presented at ESMO Asia 2025
December 9, 2025
Significant Improvement in Quality of Life Reported in Updated HARMONi-6 Data for Ivonescimab at ESMO Asia
December 9, 2025
All Approved Indications of Five Akeso’s Innovative Drugs Included in China’s Latest NRDL: Featuring Two First-in-Class Bispecifics with New First-Line Indications and Three Newly Negotiated Drugs
December 7, 2025
←
Previous Page
1
2